1. Pink Sheet
  2. >>Pathways & Standards

Gottlieb On Gene Therapies: 'Very Seductive' To Think About Accelerated Approval Pathway

 
• By Michael Cipriano

Accelerated approval would help agency monitor gene therapies for durability and off-target effects, US FDA commissioner says.

Genetic Medicine with dna isolated on white.3d rendering

As the US FDA plans to release guidance clarifying its approach for regulating gene therapies, agency Commissioner Scott Gottlieb provided some insight into the agency's thinking on the subject when he called it "very seductive" to think about the accelerated approval pathway for such therapies.

Speaking at the Reagan-Udall Foundation's annual meeting May 4, Gottlieb stressed that the most critical questions in the review of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

US FDA Acting Drug Center Chief Corrigan-Curay Retiring, Senior Staff Remake Continues

 
• By Derrick Gingery

The news coincides with rumors that Commissioner Martin Makary soon will name a new Center for Drug Evaluation and Research director.

New EU Filings

 
• By Neena Brizmohun

Linerixibat, GSK's treatment for cholestatic pruritus in patients with primary biliary cholangitis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

 
• By Michael McCaughan

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.

National Priority Voucher Gives US FDA Commissioner Tool For Radical Regulatory Surgery

 
• By Bridget Silverman

US FDA Commissioner Martin Makary will establish "national priorities" used to select sponsors for the pilot of “tumor board-style” drug reviews that would start before Phase III is completed.

More from Pathways & Standards